Wednesday, September 25, 2013
• Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase II trial, titled “Therapeutic Trial of EPI-743 in Patients with Disorders of Energy Utilization or Oxidation-Reduction.” The crossover study will randomize patients to receive either EPI-743 treatment or placebo for six months before being crossed over to the other arm.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.